EVALUATION OF CITALOPRAM AFFECTED THE GENERALIZED ANXIETY DISORDER PARTICIPANTS’ QUALITY OF LIFE. Int. Res. J. Pharm. 2023;14(11):21-25. doi:10.56802/kedfgd52